Ignite Creation Date:
2024-05-06 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 2:28 PM
Study NCT ID:
NCT05302583
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2022-03-21
Brief Title:
Aromatherapy Inhaler Use for HSCT Distress
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research is to evaluate aromatherapy inhaler use and how it may impact cancer distress and coping by patients in the first few days after hematopoietic stem cell transplant HSCT
Detailed Description:
Phase 1 Transplant Day 1 2 or 3 Phase 2 Washout Day Standard of care SOC pharmacological intervention only Phase 3 Transplant Day 3 4 or 5 Study Completion Transplant Day 4 5 or 6
Study activities will occur on a single day for each phase However a three-day window for Phases 1 and 3 will allow consideration of patients ability to participate in the immediate post-transplant period
Study activities will occur on a single day for each phase However a three-day window for Phases 1 and 3 will allow consideration of patients ability to participate in the immediate post-transplant period
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None